
Avalere Health Group
Proposed Changes to Best Price and Market Dynamics
Pages
13
Time to read
16 mins
Publication
Language
English

Pages
13
Time to read
16 mins
Publication
Language
English
This analytical report examines the CMS's proposed changes to the Best Price definition under the Medicaid Drug Rebate Program. It explores potential impacts on drug pricing, Medicaid rebate liabilities, and market dynamics for stakeholders including manufacturers, payers, and providers. The report highlights implications for commercial payer rebates, channel discounts, and innovative arrangements, providing insights into how these changes could reshape the healthcare landscape.